BitFuFu Announces April 2025 Bitcoin Mining and Operation Updates

1 day ago

Total hashrate under management reached 28.3 EH/s as of April 30, 2025, a 37.4% month-over-month increase.Total power capacity under management…

UK Online Shoppers Can Try on Their Next Fashion Purchase Using a 3D Avatar

1 day ago

- Online sizing technology provider, Makip, has upgraded its flagship product, Unisize, to provide a 3D avatar sizing display as…

TEGNA Inc. Reports First Quarter 2025 Results and Provides Second Quarter Guidance

1 day ago

Achieves first quarter key guidance metrics Reaffirms 2024/2025 two-year Adjusted Free Cash Flow guidance TYSONS, Va., May 08, 2025 (GLOBE…

Savaria announces the acquisition of Western Elevator Ltd.

1 day ago

LAVAL, Québec, May 08, 2025 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX:SIS), a global leader in the accessibility industry, is…

MACOM Reports Fiscal Second Quarter 2025 Financial Results

1 day ago

LOWELL, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of…

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

1 day ago

- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a…

Kelly Reports First-Quarter 2025 Earnings

1 day ago

TROY, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced…

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

1 day ago

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter…

CoreCard Corporation Reports First Quarter 2025 Results

1 day ago

NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of…

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

1 day ago

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in…

This website uses cookies.